EDIT Editas Medicine, Inc.
Price Chart
Executive Summary
Editas Medicine presented preclinical data for EDIT-401 at the EAS Congress, showing a single dose achieved ~90% mean reductions in LDL-C, Lp(a), and ApoB in non-human primates. The company also received positive pre-IND feedback from the FDA and plans to submit a CTN in Australia by mid-2026, with early human proof-of-concept data expected by end of 2026. For an early-stage biotech with a $270M market cap, this is a significant pipeline catalyst that supports the stock's bullish narrative.
Actionable Insight
EDIT-401's preclinical data is highly encouraging with ~90% reductions across multiple atherogenic lipoproteins, positioning it as a potential best-in-class therapy for hyperlipidemia. The positive FDA feedback and clear regulatory path to human trials by mid-2026 are key catalysts. Traders should monitor for CTN submission and early proof-of-concept data by year-end 2026, which could drive significant upside given the large addressable market.
Key Facts
- Single dose of EDIT-401 achieved ~90% mean reduction in LDL-C, Lp(a), and ApoB in NHPs
- Reductions were rapid, dose-dependent, and highly correlated, supporting unified LDLR upregulation mechanism
- Positive pre-IND feedback received from FDA on nonclinical package, CMC plans, and study design
- Company plans to submit CTN in Australia by mid-2026 for first-in-human trial in HeFH patients
- Early in vivo human proof-of-concept data for EDIT-401 expected by end of 2026
- EDIT-401 was well-tolerated in ongoing GLP toxicology study with no adverse observations at 1.5 mg/kg
Financial Impact
No financial data provided; pipeline catalyst for a pre-revenue biotech with $270M market cap
Risk Factors
- Preclinical results may not translate to human efficacy or safety
- Regulatory approval for clinical trials is not guaranteed despite positive pre-IND feedback
- Company is pre-revenue with limited cash runway; potential need for future financing
- Competition from existing PCSK9 inhibitors and other gene editing approaches
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300882 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $2.49 awaiting T+5 | awaiting T+5 | — | $2.50 (+0.60%) |
|
May 26, 2026
17d ago
|
424B5
| $3.57 $2.82 | ▲ +21.01% | ▲ +22.22% | $2.50 (+29.97%) |
|
May 26, 2026
17d ago
|
8-K
| $3.57 $2.82 | ▲ +21.01% | ▲ +22.22% | $2.50 (+29.97%) |
|
May 26, 2026
18d ago
|
Press Release
| $3.08 $3.34 | ▼ −8.44% | ▼ −7.36% | $2.50 (+18.83%) |
|
May 26, 2026
18d ago
|
8-K
| $3.08 $3.34 | ▲ +8.44% | ▲ +7.36% | $2.50 (−18.83%) |
|
May 26, 2026
18d ago
|
424B5
| $3.08 $3.34 | ▼ −8.44% | ▼ −7.36% | $2.50 (+18.83%) |
|
May 26, 2026
18d ago
|
Press Release
| $3.08 $3.34 | ▼ −8.44% | ▼ −7.36% | $2.50 (+18.83%) |
|
May 26, 2026
18d ago
|
Press Release
| $3.08 $2.82 | ▼ −8.44% | ▼ −9.65% | $2.50 (−18.83%) |
|
May 14, 2026
4w ago
|
8-K
| $2.85 $2.67 | ▼ −6.32% | ▼ −5.60% | $2.50 (−12.28%) |
|
May 14, 2026
4w ago
|
Press Release
| $2.85 $2.67 | ▼ −6.32% | ▼ −5.60% | $2.50 (−12.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access